The echinocandin caspofungin impairs the innate immune mechanism against Candida parapsilosis

International Journal of Antimicrobial Agents

Volumn 33, Issue 1, 2009, Pages 21-26

  van Asbeck, E C ^a   Hoepelman, A I M ^b   Scharringa, J ^a   Verhoef, J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Candida parapsilosis; Caspofungin; Intracellular killing; Opsonisation; Phagocytosis

Indexed keywords

BETA GLUCAN; CASPOFUNGIN; ECHINOCANDIN; OPSONIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BROTH DILUTION; CANDIDA PARAPSILOSIS; CHEMOLUMINESCENCE; FUNGUS ISOLATION; HUMAN; HUMAN CELL; INNATE IMMUNITY; INTRACELLULAR KILLING; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RESPIRATORY BURST; YEAST CELL;

ANTIFUNGAL AGENTS; CANDIDA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HUMANS; IMMUNITY, INNATE; MICROBIAL SENSITIVITY TESTS; NEUTROPHILS; OPSONIN PROTEINS; PHAGOCYTOSIS; RESPIRATORY BURST;

EID: 59349117356     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.06.013     Document Type: Article

References (51)

1. Pfaller M.A., Jones R.N., Doern G.V., Fluit A.C., Verhoef J., Sader H.S., et al., SENTRY Participant Group (Europe). International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn Microbiol Infect Dis 35 (1999) 19-25
2. Pfaller M.A., Jones R.N., Doern G.V., Sader H.S., Messer S.A., Houston A., et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 44 (2000) 747-751
3. Sandven P. Epidemiology of candidemia. Rev Iberoam Micol 17 (2000) 73-81
4. Sarvikivi E., Lyytikainen O., Soll D.R., Pujol C., Pfaller M.A., Richardson M., et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 43 (2005) 2729-2735
5. Krcmery V., and Barnes A.J. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 50 (2002) 243-260
6. Levin A.S., Costa S.F., Mussi N.S., Basso M., Sinto S.I., Machado C., et al. Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn Microbiol Infect Dis 30 (1998) 243-249
7. Levy I., Rubin L.G., Vasishtha S., Tucci V., and Sood S.K. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 26 (1998) 1086-1088
8. Weems Jr. J.J., Chamberland M.E., Ward J., Willy M., Padhye A.A., and Solomon S.L. Candida parapsilosis fungemia associated with parenteral nutrition and contaminated blood pressure transducers. J Clin Microbiol 25 (1987) 1029-1032
9. Marodi L., Korchak H.M., and Johnston Jr. R.B. Mechanisms of host defense against Candida species. I. Phagocytosis by monocytes and monocyte-derived macrophages. J Immunol 146 (1991) 2783-2789
10. Marodi L., Forehand J.R., and Johnston Jr. R.B. Mechanisms of host defense against Candida species. II. Biochemical basis for the killing of Candida by mononuclear phagocytes. J Immunol 146 (1991) 2790-2794
11. Roilides E., Walsh T.J., Rubin M., Venzon D., and Pizzo P.A. Effects of antifungal agents on the function of human neutrophils in vitro. Antimicrob Agents Chemother 34 (1990) 196-201
12. van Spriel A.B., van den Herik-Oudijk I.E., van Sorge N.M., Vile H.A., van Strijp J.A., and van de Winkel J.G. Effective phagocytosis and killing of Candida albicans via targeting FcγRI (CD64) or FcαRI (CD89) on neutrophils. J Infect Dis 179 (1999) 661-669
13. Raponi G., Keller N., Rozenberg-Arska M., Hoepelman I.M., and Verhoef J. The influence of cefepime on opsonophagocytosis of bacteria. Drugs Exp Clin Res 15 (1989) 141-144
14. Raponi G., Vreede R.W., Rozenberg-Arska M., Hoepelman I.M., Keller N., and Verhoef J. The influence of subminimal inhibitory concentrations of netilmicin and ceftriaxone on the interaction of Escherichia coli with host defences. J Antimicrob Chemother 23 (1989) 565-576
15. Keller N., Raponi G., Hoepelman I.M., Overbeek B.P., Rozenberg-Arska M., and Verhoef J. Effect of sub-minimal inhibitory concentrations of ciprofloxacin and fleroxacin on the bacterial capsular antigen and opsonophagocytosis by human polymorphonuclear leukocytes. Zentralbl Bakteriol 274 (1991) 519-526
16. Richardson M.D., Scott G., and Shankland G.S. Effect of cilofungin on phagocytosis and intracellular killing of Candida albicans by human neutrophils. Eur J Clin Microbiol Infect Dis 11 (1992) 22-26
17. Denning D.W. Echinocandin antifungal drugs. Lancet 362 (2003) 1142-1151
18. Deresinski S.C., Stevens D.A., and Caspofungin. Clin Infect Dis 36 (2003) 1445-1457
19. Cappelletty D., and Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 27 (2007) 369-388
20. Fleck R., Dietz A., and Hof H. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother 59 (2007) 767-771
21. Pfaller M.A., Diekema D.J., Messer S.A., Hollis R.J., and Jones R.N. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 47 (2003) 1068-1071
22. Pfaller M.A., Boyken L., Hollis R.J., Messer S.A., Tendolkar S., and Diekema D.J. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 44 (2006) 760-763
23. Laverdiere M., Labbe A.C., Restieri C., Rotstein C., Heyland D., Madger S., et al. Susceptibility patterns of Candida species recovered from Canadian intensive care units. J Crit Care 22 (2007) 245-250
24. Nakamura T., and Takahashi H. Epidemiological study of Candida infections in blood: susceptibilities of Candida spp. to antifungal agents, and clinical features associated with the candidemia. J Infect Chemother 12 (2006) 132-138
25. Abruzzo G.K., Flattery A.M., Gill C.J., Kong L., Smith J.G., Pikounis V.B., et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 41 (1997) 2333-2338
26. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 20 (2003) 121-136
27. Mora-Duarte J., Betts R., Rotstein C., Colombo A.C., Thompson-Moya L., Smietana J., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
28. Moudgal V., Little T., Boikov D., and Vazquez J.A. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 49 (2005) 767-769
29. Deresinski S.C., Clemons K.V., Kemper C.A., Roesch K., Walton B., and Stevens D.A. Genotypic analysis of pseudoepidemic due to contamination of Hanks' balanced salt solution with Candida parapsilosis. J Clin Microbiol 33 (1995) 2224-2226
30. Scherer S., and Stevens D.A. Application of DNA typing methods to epidemiology and taxonomy of Candida species. J Clin Microbiol 25 (1987) 675-679
31. van Asbeck E.C., Huang Y.C., Markham A.N., Clemons K.V., and Stevens D.A. Candida parapsilosis fungemia in neonates: genotyping results suggest healthcare workers hands as source, and review of published studies. Mycopathologia 164 (2007) 287-293
32. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast. 2nd ed. Approved standard. M27-A2. Wayne, PA: NCCLS; 2002.
33. Troelstra A., Giepmans B.N., Van Kessel K.P., Lichenstein H.S., Verhoef J., and van Strijp J.A. Dual effects of soluble CD14 on LPS priming of neutrophils. J Leukoc Biol 61 (1997) 173-178
34. Rooijakkers S.H., Ruyken M., Roos A., Daha M.R., Presanis J.S., Sim R.B., et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat Immunol 6 (2005) 920-927
35. Vidarsson G., van der Pol W.L., van Den Elsen J.M., Vile H., Jansen M., Duijs J., et al. Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J Immunol 166 (2001) 6250-6256
36. Green L.J., Marder P., Mann L.L., Chio L.C., and Current W.L. LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability. Antimicrob Agents Chemother 43 (1999) 830-835
37. Stevens D.A., Espiritu M., and Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 48 (2004) 3407-3411
38. Torres-Rodriguez J.M., Carrillo-Munoz A., Gallach-Bau C., and Madrenys N. Susceptibility of Candida species to cilofungin (LY-121019). Mycoses 32 (1989) 316-318
39. Chiller T., Farrokhshad K., Brummer E., and Stevens D.A. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn Microbiol Infect Dis 39 (2001) 99-103
40. Kristian S.A., Timmer A.M., Liu G.Y., Lauth X., Sat-Man N., Rosenfeld Y., et al. Impairment of innate immune killing mechanisms by bacteriostatic antibiotics. FASEB J 21 (2007) 1107-1116
41. Chamilos G., Lewis R.E., Albert N., and Kontoyiannis D.P. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 51 (2007) 2257-2259
42. Clemons K.V., Espiritu M., Parmar R., and Stevens D.A. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 50 (2006) 1293-1297
43. Fleischhacker M., Radecke C., Schulz B., and Ruhnke M. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J Clin Microbiol Infect Dis 27 (2008) 127-131
44. Stevens D.A., White T.C., Perlin D.S., and Selitrennikoff C.P. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 51 (2005) 173-178
45. Gelfand J.A., Hurley D.L., Fauci A.S., and Frank M.M. Role of complement in host defense against experimental disseminated candidiasis. J Infect Dis 138 (1978) 9-16
46. Han Y., Kozel T.R., Zhang M.X., MacGill R.S., Carroll M.C., and Cutler J.E. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J Immunol 167 (2001) 1550-1557
47. Zhang M.X., Brandhorst T.T., Kozel T.R., and Klein B.S. Role of glucan and surface protein BAD1 in complement activation by Blastomyces dermatitidis yeast. Infect Immun 69 (2001) 7559-7564
48. Hohl T.M., Feldmesser M., Perlin D.S., and Pamer E.G. Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal β-glucan exposure. Proceedings of the 45th annual meeting of the Infectious Diseases Society of America (IDSA). San Diego, CA, October 4-7 (2007)
49. Chamilos G., Lewis R.E., and Kontoyiannis D.P. Inhibition of Candida parapsilosis mitochondrial respiratory pathways enhances susceptibility to caspofungin. Antimicrob Agents Chemother 50 (2006) 744-747
50. Frank U., Greiner M., Engels I., and Daschner F.D. Effects of caspofungin (MK-0991) and anidulafungin (LY303366) on phagocytosis, oxidative burst and killing of Candida albicans by human phagocytes. Eur J Clin Microbiol Infect Dis 23 (2004) 729-731
51. Meshulam T., Levitz S.M., Diamond R.D., and Sugar A.M. Effect of cilofungin (LY121019), a fungal cell wall synthesis inhibitor, on interactions of Candida albicans with human neutrophils. J Antimicrob Chemother 24 (1989) 741-745